Abbott: Data Show Long-Term Benefits Of MitraClip Device For Treating Secondary Mitral Regurgitation
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Abbott (ABT) said new five-year data from Landmark COAPT trial reinforced the long-term safety and effectiveness of MitraClip device for treating secondary mitral regurgitation.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-465830317-72a07789a32346fea9e7a03b136d0060-f0f6c5eb79a8488594a827a5dbc4d404-ee5cf1a13bf5410caf16dbe25a019d7f.jpg "A Guide to Reselling Toys at the Holidays for Extra Money")